You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新華製藥(000756.SZ):硫酸氫氯吡格雷片上市許可持有人轉讓補充申請獲批
格隆匯 03-03 16:40

格隆匯3月3日丨新華製藥(000756.SZ)公佈,近日,山東新華製藥股份有限公司收到國家藥品監督管理局核准簽發的硫酸氫氯吡格雷片(簡稱“本品”)《藥品補充申請批准通知書》,批准本品上市許可持有人轉讓補充申請。

硫酸氫氯吡格雷片為循環系統疾病藥物,係一種前體藥物,其代謝產物之一是血小板聚集抑制劑。氯吡格雷必須通過CYP450酶代謝,生成能抑制血小板聚集的活性代謝物。氯吡格雷的活性代謝產物選擇性地抑制二磷酸腺昔(ADP)與其血小板P2Y12受體的結合及繼發的ADP介導的糖蛋白GPIIb/IIIa複合物的活化,因此可抑制血小板聚集。主要適用於以下患者,預防動脈粥樣硬化血栓形成事件:近期心肌梗死患者(從幾天到小於35天),近期缺血性卒中患者(從7天到小於6個月)或確診外周動脈性疾病的患者;急性冠脈綜合徵的患者:非ST段抬高性急性冠脈綜合徵(包括不穩定性心絞痛或非Q波心肌梗死),包括經皮冠狀動脈介入術後置入支架的患者,與阿司匹林合用;用於ST段抬高性急性冠脈綜合徵患者,與阿司匹林聯合,可合併在溶栓治療中使用。

根據有關統計數據顯示,2023年中國公立醫療機構硫酸氫氯吡格雷片的年度銷售額約為人民幣59.43億元;2024年上半年中國公立醫療機構銷售額約為人民幣32.16億元,其中75mg規格銷售額佔比89.01%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account